Cargando…
Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
BACKGROUND: Long Covid is an emerging chronic illness potentially affecting millions, sometimes preventing the ability to work or participate in normal daily activities. COVID-OUT was an investigator-initiated, multi-site, phase 3, randomized, quadruple-blinded placebo-controlled clinical trial (NCT...
Autores principales: | Bramante, Carolyn T., Buse, John B., Liebovitz, David, Nicklas, Jacinda, Puskarich, Michael A., Cohen, Ken, Belani, Hrishikesh, Anderson, Blake, Huling, Jared D., Tignanelli, Christopher, Thompson, Jennifer, Pullen, Matthew, Siegel, Lianne, Proper, Jennifer, Odde, David J., Klatt, Nichole, Sherwood, Nancy, Lindberg, Sarah, Wirtz, Esteban Lemus, Karger, Amy, Beckman, Kenny, Erickson, Spencer, Fenno, Sarah, Hartman, Katrina, Rose, Michael, Patel, Barkha, Griffiths, Gwendolyn, Bhat, Neeta, Murray, Thomas A., Boulware, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810227/ https://www.ncbi.nlm.nih.gov/pubmed/36597543 http://dx.doi.org/10.1101/2022.12.21.22283753 |
Ejemplares similares
-
68 Metformin prevents the diagnosis of Long Covid in phase 3 trial of early treatment.
por: Bramante, Carolyn, et al.
Publicado: (2023) -
Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2
por: Avula, Nandini, et al.
Publicado: (2023) -
Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms
por: Bramante, Carolyn T, et al.
Publicado: (2022) -
Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial
por: Bramante, Carolyn T, et al.
Publicado: (2023) -
Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)